All In Biotech

NDA 018337 · Taro

Acetaminophen

Acetaminophen · Rectal

Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1980

Apr 22, 1980

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,695

325 Phase 3, 144 recruiting

FAERS reports

261,279

227,860 serious, 51,167 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 3, 2026.

Uses temporarily reduces fever relieves minor aches, pains, and headache

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 22, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • ACETAMINOPHEN · ACETAMINOPHEN 120MG · SUPPOSITORY, RECTAL · Over-the-counter
  • ACETAMINOPHEN · ACETAMINOPHEN 650MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SUPPOSITORY, RECTAL · Discontinued
  • INFANTS' FEVERALL · ACETAMINOPHEN 80MG · SUPPOSITORY, RECTAL · Over-the-counter
  • ACETAMINOPHEN · ACETAMINOPHEN 325MG · SUPPOSITORY, RECTAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Acetaminophen" as an intervention, any sponsor and status, largest first.

All 1,695 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use23,643
  • fatigue21,355
  • drug ineffective19,055
  • pain18,805
  • nausea18,668
  • headache17,530
  • toxicity to various agents16,856
  • dyspnoea15,395
  • vomiting14,905
  • pyrexia14,843
  • arthralgia14,758
  • diarrhoea14,080

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,590
20052,685
20063,150
20072,550
20083,882
20093,069
20103,843
20118,184
20128,165
20133,385
20144,018
20156,122
20168,307
20177,474
20189,223
201912,638
202019,805
202120,050
202227,215
202327,956
202428,660
202528,275
202620,022

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Acetaminophen (Acetaminophen)

2024 spending

$126K

Beneficiaries

305

734 claims

Per beneficiary

$413

$0.20 per unit

View as table
YearSpending
2020$0
2021$35,877
2022$59,928
2023$48,943
2024$125,891

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,612 on PubMed

Sponsor: Taro · Also marketed as Infants' Feverall

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.